Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05068336 |
Other study ID # |
514-192-32 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
August 25, 2021 |
Est. completion date |
November 4, 2021 |
Study information
Verified date |
November 2021 |
Source |
Kocaeli Derince Education and Research Hospital |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
The glycocalyx is a dynamic and complex biochemical structure composed of proteoglycans,
glycoproteins, and soluble proteins. The glycocalyx interacts with various proteins such as
albumin and orosomucoid to form a thick surface layer on the vessel surface that is
physiologically active. This is called the endothelial surface layer. This structure is
constantly changing with the blood flowing in the vein. The glycocalyx regulates oncotic
pressure and also prevents leukocyte and platelet adhesion to the endothelium. Endothelial
cell dysfunction is a valuable marker of increased vascular permeability and impaired
angiogenesis due to cardiovascular, thoracic, renal, and metabolic diseases.
Description:
The glycocalyx is a dynamic and complex biochemical structure composed of proteoglycans,
glycoproteins, and soluble proteins. The glycocalyx interacts with various proteins such as
albumin and orosomucoid to form a thick surface layer on the vessel surface that is
physiologically active. This is called the endothelial surface layer. This structure is
constantly changing with the blood flowing in the vein. The glycocalyx regulates oncotic
pressure and also prevents leukocyte and platelet adhesion to the endothelium. Endothelial
cell dysfunction is a valuable marker of increased vascular permeability and impaired
angiogenesis due to cardiovascular, thoracic, renal, and metabolic diseases.
Some medical approaches, including anti-thrombin III, nitric oxide, the TNF-α analog
etanercept, and inhalation agents, can repair or prevent deterioration of the endothelial
glycocalyx. In a study by Chen et al., it was shown that Sevoflurane has a protective effect
on syndecan and heparan sulfate, which are located in the glycocalyx structure, thus reducing
leukocyte and platelet adhesion and protecting the vascular endothelium (8).
Kim et al. In a study conducted, it was shown that the protective effect of propofol, an
intravenous anesthetic, on the vascular endothelium was greater than that of sevoflurane In
our research, no study was found on the effect of another inhalation anesthetic, desflurane,
on the vascular glycocalyx structure. In this study, we aimed to investigate and compare the
effects of sevoflurane and desflurane on glycocalyx.